Raxibacumab (Human Genome Sciences, Inc.)
Welcome to the PulseAid listing for the Raxibacumab drug offered from Human Genome Sciences, Inc.. This Anthrax Protective Antigen-directed Antibody [EPC],Anthrax Protective Antigen-directed Antibody Interactions [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Human Genome Sciences, Inc. |
NON-PROPRIETARY NAME: | raxibacumab |
SUBSTANCE NAME: | RAXIBACUMAB |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Anthrax Protective Antigen-directed Antibody [EPC],Anthrax Protective Antigen-directed Antibody Interactions [MoA] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | INJECTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2012-12-14 |
END MARKETING DATE: | 0000-00-00 |
Raxibacumab HUMAN PRESCRIPTION DRUG Details:
Item Description | Raxibacumab from Human Genome Sciences, Inc. |
LABELER NAME: | Human Genome Sciences, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 50(mg/mL) |
START MARKETING DATE: | 2012-12-14 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 49401-103_ac00d3a1-b7ad-4ec7-a870-fbc25d883176 |
PRODUCT NDC: | 49401-103 |
APPLICATION NUMBER: | BLA125349 |
Other RAXIBACUMAB Pharmaceutical Manufacturers / Labelers: